Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | CBFB | Q13951 | 1/20 | 0.38 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL711950 | 0.92 | CYP3A4 (0.39) | MAOBCBFB | |
| SCHEMBL9071889 | 0.91 | SYK (0.43) | SMOMAPK14APPMAPTCBFB | |
| Trifluoroacetic Acid SCHEMBL709562 | 0.89 | SMO (0.40) | SMOMAOBMAPTCSNK2A2CSNK2A1 | |
| Trifluoroacetic Acid SCHEMBL710197 | 0.88 | MAOB (0.36) | MAOBDHODHGPR132PPARG | |
| Trifluoroacetic Acid SCHEMBL709199 | 0.88 | PTPN1 (0.43) | SMOMAPK14APPMAPTDHODH | |
| Trifluoroacetic Acid SCHEMBL709893 | 0.85 | PDE4A (0.40) | ADAMTS4 | |
| Trifluoroacetic Acid SCHEMBL711385 | 0.85 | CYP3A4 (0.39) | MAOBCBFBGPR132 | |
| Trifluoroacetic Acid SCHEMBL713332 | 0.83 | KMT2A (0.41) | SMOMAPK14APPMAPTDHODH | |
| SCHEMBL9071894 | 0.83 | CYP3A4 (0.46) | MAOBCBFB | |
| Trifluoroacetic Acid SCHEMBL711971 | 0.82 | CYP3A4 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940837-B1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| EP-1940837-A2 | IMIDAZOPYRIDINE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | SMO 4431/4885MAPK14 760/4885MAOB 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.